The Oncology Deep Dive podcast

Ivonescimab Beats Keytruda: Oncology's Biggest Data Weekend

0:00
22:58
Spol 15 sekunder tilbage
Spol 15 sekunder frem

What happens when a cancer drug works exactly as designed — stops the tumor for months — but the patient dies sooner? That paradox runs through the biggest oncology dataweekend of the year.

We distill the data drop from the World Conference on Lung Cancer (WCLC) in Seoul: Ivonescimab beating Keytruda head-to-head in first-line non-small cell lung cancer, theDESTINY-Lung04 survival paradox, two same-day breakthroughs that revived smallcell lung cancer after decades of stagnation, and what the wave of genericsmeans for the oncology "blockbuster."

We cut through the jargon on bispecific antibodies, antibody-drug conjugates, and BiTEs — and why sequencing may now matter as much as the drug itself.

Disclaimer:AI-generated from publicly available news. Not medical or investment advice.May contain errors — verify against primary sources.

00:00 The Survival Paradox

00:32 Welcome to the Deep Dive

01:19 HARMONI-2: Ivonescimab vs Keytruda

02:25 How Bispecific Antibodies Work

03:13 The Survival Numbers

04:18 The Single-Region Trial Caveat

05:18 Merck's Response

06:04 DESTINY-Lung04: The Paradox

06:40 How Antibody-Drug Conjugates Work

08:10 Why the Survival Paradox Happens

09:29 A Curveball: Sevabretinib

11:10 RESILIENT-3: Cullinan vs J&J

14:37 Small Cell: The Graveyard Awakens

16:12 Amgen's BiTE: Molecular Handcuffs

17:09 Sequencing, Not Competing

18:08 Diagnostics & Disease Interception

19:38 Where the Venture Capital Flows

20:22 The Generics Reality Check

21:07 The End of the Blockbuster Era?

Flere episoder fra "The Oncology Deep Dive"